Recombinant SARS-CoV-2 S protein (F817P, A892P, A899P, A942P, K986P, V987P), His Tag (MALS verified), 50µg

Background
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 S protein, His Tag (SPN-C52Hd) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1). Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 138.2 kDa. The protein is cleaved at furin site and divided into S1 (16-685) and S2 (686-1213). The protein migrates as 75-85 kDa, 90-100 kDa and 150-160 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Inactivation mechanism of cold plasma combined with 222 nm ultraviolet for spike protein and its application in disinfecting of SARS-CoV-2"
Sheng, Wang, Zhao et al
J Hazard Mater (2024) 465, 133458
(2) "Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines"
Ou, Baillet, Picece et al
ACS Nano (2024)
(3) "The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health"
Satapathy, Kumar, Gupta et al
Int J Surg (2024)
Showing 1-3 of 35282 papers.